The standard treatment for intermediate-risk stage I/IIA cervical cancer that has been surgically removed is radiation therapy after surgery to reduce the risk of cancer recurrence. The purpose of this study is to see if adding the chemotherapy drug cisplatin to radiation therapy further extends the time to disease recurrence compared with radiation therapy alone. The combination of chemotherapy and radiation therapy has been shown to extend survival in women with higher-risk cervical cancer, but its effectiveness in women with disease that has an intermediate risk of recurring is not known.
Patients will be randomly assigned to receive radiation therapy plus cisplatin or radiation therapy alone after surgery. They will also be asked to complete quality-of-life questionnaires asking how they feel physically and emotionally during cancer treatment. Researchers also want to know about patients’ smoking histories since cervical cancer is associated with smoking.